Jafar S, Rodriguez-Barradas M, Graham D Y, Butel J S
Division of Molecular Virology, Baylor College of Medicine, Houston, Texas 77030, USA.
J Med Virol. 1998 Apr;54(4):276-84. doi: 10.1002/(sici)1096-9071(199804)54:4<276::aid-jmv7>3.0.co;2-1.
SV40 is a simian polyomavirus that was a contaminant of some viral vaccines administered to people between 1955 and 1962. SV40 DNA has recently been found associated with several types of human tumors, suggesting that the virus is present in humans. We examined sera from patients infected with human immunodeficiency virus type 1 (HIV-1) as well as from HIV-1-negative controls to determine the prevalence of SV40 neutralizing antibodies using a specific plaque reduction assay. We found that 16.1% of HIV-infected patients (n = 236) were seropositive for SV40, as compared to 12.0% of HIV-negative control volunteers (n = 108) and 11.1% of HIV-negative patients (n = 72). These differences were not statistically significant. As individuals born between 1941 and 1962 had the highest chance of having received SV40-contaminated poliovaccines, we analyzed SV40 seropositivity rates based on year of birth. SV40 antibody rates for HIV-infected patients born before 1941, between 1941 and 1962, and after 1962 were 17.1%, 16.3%, and 11.8%, respectively. For the HIV-negative subjects, the rates were 12.5%, 12.0%, and 9.7%, respectively. There was no correlation between SV40 seropositivity and either the stage of disease in HIV-infected patients or the race/ethnicity. Also, there was no correlation between the presence of SV40 neutralizing antibody and the titer of neutralizing antibody to human polyomavirus BKV. The SV40 seropositivity rates in the patients born between 1941 and 1962 may be explained by the likelihood of those individuals having received SV40-contaminated vaccines, but the detection of SV40 neutralizing antibody in individuals born after 1962 (with no risk of having received contaminated vaccines) is significant. Although cross-reactive antibodies might theoretically contribute to the observed reactivities, these results suggest that SV40 neutralizing antibodies are present in certain individuals and raise the possibility that SV40 continues to infect humans long after vaccines were freed from contamination.
SV40是一种猿猴多瘤病毒，曾是1955年至1962年间用于人类的某些病毒疫苗的污染物。最近发现SV40 DNA与几种人类肿瘤有关，这表明该病毒存在于人类体内。我们使用特定的蚀斑减少试验检测了1型人类免疫缺陷病毒（HIV-1）感染患者以及HIV-1阴性对照者的血清，以确定SV40中和抗体的流行率。我们发现，16.1%的HIV感染患者（n = 236）SV40血清学呈阳性，相比之下，HIV阴性对照志愿者中这一比例为12.0%（n = 108），HIV阴性患者中为11.1%（n = 72）。这些差异无统计学意义。由于1941年至1962年间出生的个体接种受SV40污染的脊髓灰质炎疫苗的可能性最高，我们根据出生年份分析了SV40血清阳性率。1941年以前、1941年至1962年间以及1962年以后出生的HIV感染患者的SV40抗体率分别为17.1%、16.3%和11.8%。对于HIV阴性受试者，相应的比率分别为12.5%、12.0%和9.7%。SV40血清阳性与HIV感染患者的疾病阶段或种族/民族均无相关性。此外，SV40中和抗体的存在与人类多瘤病毒BKV中和抗体的滴度也无相关性。1941年至1962年间出生的患者中SV40血清阳性率可能是因为这些个体接种了受SV40污染疫苗，但在1962年以后出生（无接种污染疫苗风险）的个体中检测到SV40中和抗体则具有重要意义。虽然理论上交叉反应抗体可能导致观察到的反应性，但这些结果表明某些个体中存在SV40中和抗体，并增加了一种可能性，即SV40在疫苗不再受污染后很长时间仍继续感染人类。
